ACI Group Ltd (U.K.) has announced its partnership with DolCas Biotech LLC (New Jersey) to distribute its range of clinically researched nutraceutical ingredients in the U.K. market.
The collaboration strengthens ACI Group’s functional ingredient portfolio at a crucial time. According to intelligence firm Grand View Research, the global nutraceuticals market is expected to grow at a compound annual growth rate (CAGR) of 8.4 percent from 2024 to 2030, driven by increasing consumer focus on proactive health management.
“This partnership with DolCas Biotech opens doors for our customers to create truly differentiated products that command attention,” said Karsten Smet, CEO of ACI Group. “In today’s competitive market, brands and their formulators need ingredients that not only work in a targeted way to address critical health priorities but substantiates those claims. DolCas Biotech’s clinically proven range, with focus on superior bioavailability and potency, supports the development of innovative formulations that meet consumer demands for efficacy and ease of use. We look forward to supplying these ingredients to our health and nutrition customers across the U.K. and helping to usher in the next generation of nutraceutical solutions.”
The partnership brings several key products to the U.K. market, including Curcugen, Morikol, BergacynFF, NitrateBurst, Fortiquin and MMP50. These ingredients enable the creation of advanced nutraceutical products with attention-grabbing features and benefits.
For instance, the high potency of Morikol and NitrateBurst enables brands to offer collagen and phytonitrate supplements in convenient tablet or capsule forms, rather than the traditional powders requiring 5-20 g daily doses.
“We’re delighted to partner with ACI Group to introduce our innovative ingredients to the U.K. market. Today’s nutraceutical market is all about building trust; consumers are increasingly engaged, but equally skeptical in their search for products that are effective and safe,” said KG Rao, founder & CEO at DolCas Biotech. “We are intentional in our efforts to develop clinically researched ingredients that intelligently meet at the crossroads of high quality and optimized processing. Owing to this, our ingredients outperform many of their industry counterparts in bioavailability, potency, and solubility, positioning them for distinction and market dominance. The ACI Group is an experienced and established player in the functional ingredient market, making them a well-matched distribution partner for us.”
For more information, visit www.acigroup.biz or https://dolcas-biotech.com.
